Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Clindamycin + erythromycin** is a combination of two antibiotics, both of which are lincosamide and macrolide class antimicrobials, respectively. They inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit, though at overlapping binding sites. This combination is rarely used clinically as a fixed product due to well-documented antagonism between the agents when used together. Both drugs are indicated for a variety of bacterial infections and have topical formulations for acne, but their concurrent use is typically discouraged outside of diagnostic laboratory settings (e.g., to detect inducible clindamycin resistance via D-zone tests). When tested together in laboratory diagnostics, their combination can reveal inducible resistance in organisms such as Staphylococcus aureus or beta-hemolytic streptococci, mediated by erm genes that modify the ribosomal target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + erythromycin.